Pfizer EBITDA 2012-2025 | PFE
Pfizer annual and quarterly EBITDA history from 2012 to 2025. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Pfizer EBITDA for the quarter ending September 30, 2025 was $5.513B, a 17.89% decline year-over-year.
- Pfizer EBITDA for the twelve months ending September 30, 2025 was $20.415B, a 61.15% increase year-over-year.
- Pfizer 2024 annual EBITDA was $19.424B, a 156.63% increase from 2023.
- Pfizer 2023 annual EBITDA was $7.569B, a 81.47% decline from 2022.
- Pfizer 2022 annual EBITDA was $40.853B, a 65.91% increase from 2021.
|
Pfizer Annual EBITDA (Millions of US $) |
|
|---|---|
| 2024 | $19,424 |
| 2023 | $7,569 |
| 2022 | $40,853 |
| 2021 | $24,624 |
| 2020 | $12,931 |
| 2019 | $12,465 |
| 2018 | $11,822 |
| 2017 | $19,991 |
| 2016 | $17,902 |
| 2015 | $16,981 |
| 2014 | $18,786 |
| 2013 | $21,594 |
| 2012 | $22,919 |
| 2011 | $22,993 |
|
Pfizer Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2025-09-30 | $5,513 |
| 2025-06-30 | $5,408 |
| 2025-03-31 | $5,356 |
| 2024-12-31 | $4,138 |
| 2024-09-30 | $6,714 |
| 2024-06-30 | $2,734 |
| 2024-03-31 | $5,838 |
| 2023-12-31 | $-2,618 |
| 2023-09-30 | $-1,611 |
| 2023-06-30 | $3,767 |
| 2023-03-31 | $8,031 |
| 2022-12-31 | $6,745 |
| 2022-09-30 | $10,126 |
| 2022-06-30 | $13,394 |
| 2022-03-31 | $10,588 |
| 2021-12-31 | $4,326 |
| 2021-09-30 | $7,488 |
| 2021-06-30 | $6,914 |
| 2021-03-31 | $5,896 |
| 2020-12-31 | $1,811 |
| 2020-09-30 | $3,656 |
| 2020-06-30 | $3,271 |
| 2020-03-31 | $4,193 |
| 2019-12-31 | $-3,799 |
| 2019-09-30 | $4,511 |
| 2019-06-30 | $5,794 |
| 2019-03-31 | $5,959 |
| 2018-12-31 | $-4,610 |
| 2018-09-30 | $5,378 |
| 2018-06-30 | $5,538 |
| 2018-03-31 | $5,516 |
| 2017-12-31 | $3,881 |
| 2017-09-30 | $5,230 |
| 2017-06-30 | $5,315 |
| 2017-03-31 | $5,565 |
| 2016-12-31 | $3,305 |
| 2016-09-30 | $4,417 |
| 2016-06-30 | $4,864 |
| 2016-03-31 | $5,316 |
| 2015-12-31 | $3,258 |
| 2015-09-30 | $4,630 |
| 2015-06-30 | $4,796 |
| 2015-03-31 | $4,297 |
| 2014-12-31 | $3,478 |
| 2014-09-30 | $5,008 |
| 2014-06-30 | $5,374 |
| 2014-03-31 | $4,926 |
| 2013-12-31 | $4,532 |
| 2013-09-30 | $5,505 |
| 2013-06-30 | $5,913 |
| 2013-03-31 | $5,644 |
| 2012-12-31 | $4,667 |
| 2012-09-30 | $5,399 |
| 2012-06-30 | $6,539 |
| 2012-03-31 | $6,314 |
| 2011-12-31 | $4,371 |
| 2011-09-30 | $6,303 |
| 2011-06-30 | $6,270 |
| 2011-03-31 | $6,049 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $147.203B | $63.627B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1019.615B | 49.05 |
| Johnson & Johnson (JNJ) | United States | $525.250B | 20.19 |
| AbbVie (ABBV) | United States | $382.020B | 22.87 |
| Roche Holding AG (RHHBY) | Switzerland | $345.793B | 0.00 |
| Novartis AG (NVS) | Switzerland | $306.534B | 16.25 |
| Merck (MRK) | United States | $275.778B | 12.85 |
| Novo Nordisk (NVO) | Denmark | $264.864B | 15.53 |
| Sanofi (SNY) | France | $112.633B | 10.89 |
| Bayer (BAYRY) | Germany | $49.829B | 8.74 |
| Innoviva (INVA) | United States | $1.465B | 7.34 |